Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus CLAFORAN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus CLAFORAN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER vs CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation, and activating autolytic enzymes.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
Terminal elimination half-life is approximately 0.6-1.2 hours in adults with normal renal function. In neonates, it is prolonged (2-6 hours). In renal impairment, half-life extends significantly (up to 15-30 hours in anuria), requiring dose adjustment.
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Small amounts are eliminated in bile (<10%) and feces (<1%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic